MARLBOROUGH, Mass. -- (BUSINESS WIRE) -- Advanced Cell Technology (ACTC) today announced that Edward Myles, Interim President, CFO & EVP of Corporate Development, will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.
Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Maxim Group and Piper Jaffray, this one-day investor conference focuses exclusively on the regenerative medicine and advanced therapies sector. The event includes clinical and commercial experts who will be on-hand to address specific questions regarding the outlook for the industry, as well as offer insight into how regenerative medicine products could impact the standard of care in key therapeutic areas. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts as well as presentations by more than 30 leading companies from across the globe.
The following are specific details regarding Advanced Cell Technology’s presentation:
ARM’s Regen Med Investor Day
|Date:||March 26, 2014|
|Location:||Metropolitan Club, One East 60th Street, New York, NY 10022|
A live-streaming webcast of all panels and company presentations will be available at: http://www.arminvestorday.com/webcast and will be published on the event’s website shortly after the conference.
Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at email@example.com. Please visit http://www.arminvestorday.com for more information.
About Advanced Cell Technology:
Advanced Cell Technology, Inc. is a Marlborough, Mass.-based biotechnology company focused on the development and commercialization of human embryonic stem cell (hESC) and adult stem cell technology. The company’s most advanced products are in clinical trials for the treatment of dry age-related macular degeneration and Stargardt’s macular degeneration. ACT’s preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. The company’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, http://www.advancedcell.com or connect with the Company on Facebook, Twitter, LinkedIn, Google+, and YouTube.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine and advanced therapies. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 150 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit www.alliancerm.org.